152 related articles for article (PubMed ID: 18558361)
1. Natural anti-Siglec autoantibodies mediate potential immunoregulatory mechanisms: implications for the clinical use of intravenous immunoglobulins (IVIg).
von Gunten S; Simon HU
Autoimmun Rev; 2008 Jun; 7(6):453-6. PubMed ID: 18558361
[TBL] [Abstract][Full Text] [Related]
2. Intravenous immunoglobulin preparations contain anti-Siglec-8 autoantibodies.
von Gunten S; Vogel M; Schaub A; Stadler BM; Miescher S; Crocker PR; Simon HU
J Allergy Clin Immunol; 2007 Apr; 119(4):1005-11. PubMed ID: 17337295
[TBL] [Abstract][Full Text] [Related]
3. Dimeric IVIG contains natural anti-Siglec-9 autoantibodies and their anti-idiotypes.
Schaub A; von Gunten S; Vogel M; Wymann S; Rüegsegger M; Stadler BM; Spycher M; Simon HU; Miescher S
Allergy; 2011 Aug; 66(8):1030-7. PubMed ID: 21385183
[TBL] [Abstract][Full Text] [Related]
4. Cell death modulation by intravenous immunoglobulin.
von Gunten S; Simon HU
J Clin Immunol; 2010 May; 30 Suppl 1():S24-30. PubMed ID: 20405180
[TBL] [Abstract][Full Text] [Related]
5. Immunologic and functional evidence for anti-Siglec-9 autoantibodies in intravenous immunoglobulin preparations.
von Gunten S; Schaub A; Vogel M; Stadler BM; Miescher S; Simon HU
Blood; 2006 Dec; 108(13):4255-9. PubMed ID: 16902148
[TBL] [Abstract][Full Text] [Related]
6. Different patterns of Siglec-9-mediated neutrophil death responses in septic shock.
von Gunten S; Jakob SM; Geering B; Takala J; Simon HU
Shock; 2009 Oct; 32(4):386-92. PubMed ID: 19295491
[TBL] [Abstract][Full Text] [Related]
7. Siglec-8 and Siglec-F, the new therapeutic targets in asthma.
Farid SSh; Mirshafiey A; Razavi A
Immunopharmacol Immunotoxicol; 2012 Oct; 34(5):721-6. PubMed ID: 22324980
[TBL] [Abstract][Full Text] [Related]
8. Patient characteristics and intravenous immunoglobulin product may affect eosinophils in Kawasaki disease.
Kuo HC; Wang CL; Wang L; Yu HR; Yang KD
Pediatr Allergy Immunol; 2008 Mar; 19(2):184-5. PubMed ID: 18257906
[No Abstract] [Full Text] [Related]
9. Regulation of airway inflammation by Siglec-8 and Siglec-9 sialoglycan ligand expression.
Schleimer RP; Schnaar RL; Bochner BS
Curr Opin Allergy Clin Immunol; 2016 Feb; 16(1):24-30. PubMed ID: 26694037
[TBL] [Abstract][Full Text] [Related]
10. Concurrent presence of agonistic and antagonistic anti-CD95 autoantibodies in intravenous Ig preparations.
Altznauer F; von Gunten S; Späth P; Simon HU
J Allergy Clin Immunol; 2003 Dec; 112(6):1185-90. PubMed ID: 14657880
[TBL] [Abstract][Full Text] [Related]
11. Discovery, Function, and Therapeutic Targeting of Siglec-8.
Youngblood BA; Leung J; Falahati R; Williams J; Schanin J; Brock EC; Singh B; Chang AT; O'Sullivan JA; Schleimer RP; Tomasevic N; Bebbington CR; Bochner BS
Cells; 2020 Dec; 10(1):. PubMed ID: 33374255
[TBL] [Abstract][Full Text] [Related]
12. Siglec-8 antibody reduces eosinophils and mast cells in a transgenic mouse model of eosinophilic gastroenteritis.
Youngblood BA; Brock EC; Leung J; Falahati R; Bochner BS; Rasmussen HS; Peterson K; Bebbington C; Tomasevic N
JCI Insight; 2019 Oct; 4(19):. PubMed ID: 31465299
[TBL] [Abstract][Full Text] [Related]
13. An anti-siglec-8 antibody depletes sputum eosinophils from asthmatic subjects and inhibits lung mast cells.
Kerr SC; Gonzalez JR; Schanin J; Peters MC; Lambrecht BN; Brock EC; Charbit A; Ansel KM; Youngblood BA; Fahy JV
Clin Exp Allergy; 2020 Aug; 50(8):904-914. PubMed ID: 32542913
[TBL] [Abstract][Full Text] [Related]
14. "Siglec"ting the allergic response for therapeutic targeting.
Bochner BS
Glycobiology; 2016 Jun; 26(6):546-52. PubMed ID: 26911285
[TBL] [Abstract][Full Text] [Related]
15. Leveraging Siglec-8 endocytic mechanisms to kill human eosinophils and malignant mast cells.
O'Sullivan JA; Carroll DJ; Cao Y; Salicru AN; Bochner BS
J Allergy Clin Immunol; 2018 May; 141(5):1774-1785.e7. PubMed ID: 28734845
[TBL] [Abstract][Full Text] [Related]
16. Mast Cell and Eosinophil Activation Are Associated With COVID-19 and TLR-Mediated Viral Inflammation: Implications for an Anti-Siglec-8 Antibody.
Gebremeskel S; Schanin J; Coyle KM; Butuci M; Luu T; Brock EC; Xu A; Wong A; Leung J; Korver W; Morin RD; Schleimer RP; Bochner BS; Youngblood BA
Front Immunol; 2021; 12():650331. PubMed ID: 33777047
[TBL] [Abstract][Full Text] [Related]
17. Sialic acid-binding immunoglobulin-like lectin (Siglec) 8 in patients with eosinophilic disorders: Receptor expression and targeting using chimeric antibodies.
Legrand F; Cao Y; Wechsler JB; Zhu X; Zimmermann N; Rampertaap S; Monsale J; Romito K; Youngblood BA; Brock EC; Makiya MA; Tomasevic N; Bebbington C; Maric I; Metcalfe DD; Bochner BS; Klion AD
J Allergy Clin Immunol; 2019 Jun; 143(6):2227-2237.e10. PubMed ID: 30543818
[TBL] [Abstract][Full Text] [Related]
18. Sialic acid-binding immunoglobulin-like lectin 8 (Siglec-8) is an activating receptor mediating β
Carroll DJ; O'Sullivan JA; Nix DB; Cao Y; Tiemeyer M; Bochner BS
J Allergy Clin Immunol; 2018 Jun; 141(6):2196-2207. PubMed ID: 28888781
[TBL] [Abstract][Full Text] [Related]
19. AK002, a Humanized Sialic Acid-Binding Immunoglobulin-Like Lectin-8 Antibody that Induces Antibody-Dependent Cell-Mediated Cytotoxicity against Human Eosinophils and Inhibits Mast Cell-Mediated Anaphylaxis in Mice.
Youngblood BA; Brock EC; Leung J; Falahati R; Bryce PJ; Bright J; Williams J; Shultz LD; Greiner DL; Brehm MA; Bebbington C; Tomasevic N
Int Arch Allergy Immunol; 2019; 180(2):91-102. PubMed ID: 31401630
[TBL] [Abstract][Full Text] [Related]
20. Human-specific expression of Siglec-6 in the placenta.
Brinkman-Van der Linden EC; Hurtado-Ziola N; Hayakawa T; Wiggleton L; Benirschke K; Varki A; Varki N
Glycobiology; 2007 Sep; 17(9):922-31. PubMed ID: 17580316
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
